Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
- Disease/Condition
- Irritable Bowel Syndrome
- Drug/Device/Intervention
- lifestyle modification
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Universität Duisburg-Essen
- Location
- Bamberg, Germany
- Phase
- N/A
- Start date
- Nov 10, 2023
- End date
- Jul 31, 2025
- Enrollment
- 118 participants
Severity of IBS symptoms by IBS-SSS,Severity of IBS symptoms by IBS-SSS,Severity of IBS symptoms by IBS-SSS,overall change in health status,overall change in health status
In the planned efficacy study, a prospective randomized controlled trial will be conducted to
 investigate the extent to which a multimodal stress reduction and lifestyle modification
 program can be reflected in patients with irritable bowel syndrome (IBS) within the framework
 of a clinical study. For this purpose, 118 patients with IBS will be enrolled in a clinical
 study. The intervention group will participate in a partial outpatient multimodal stress
 reduction and lifestyle modification program over 10 weeks, while the waitlist control group
 will only receive an educational session and written information on treatment and self-help
 options. The primary research question encompasses the examination of the program's impact on
 the severity of symptoms associated with irritable bowel syndrome (measured with the
 IBS-Symptom Severity Scale [IBS-SSS]) and additionally its influence on quality of life,
 stress, and mental well-being. Another aspect of the study is the utilization of medical
 services (e.g., comparing the number of doctor visits; intake of prescribed and
 over-the-counter medications). Additionally, a comparison of days of work disability will be
 conducted.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06145022
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06145022 through Pure Global AI's free database. This phase not specified trial is sponsored by Universität Duisburg-Essen and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 118 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.